Evotec Evotec, Hannover Medical School Partner on Multiomic Autoimmune Disease Patient Database The German medical school will analyze samples from hundreds of Sjögren's and systemic lupus erythematosus patients in search of new treatment pathways. Evotec, Takeda Pharmaceuticals Partner on RNA-Targeting Drug Development The companies will work together to identify and develop small molecule drugs against RNA targets that fit within Takeda's disease areas of focus. Evotec, Indivumed to Collaborate on Non-Small Cell Lung Cancer Drug Discovery The deal comes on the heels of a colorectal cancer-focused drug-discovery alliance that the German companies formed in early 2019. Evotec, Celmatix Partner on Women's Reproductive Health Drug Discovery About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders. Evotec Acquires iPSC Drug-Discovery Assets From Ncardia The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells. Apr 11, 2019 Evotec, Indivumed Partner on Colorectal Cancer Drug Discovery Sep 6, 2018 Evotec, Celgene Partner on Targeted Protein Degradation for Drug Discovery Aug 27, 2018 Centogene, Evotec Forge Drug-Discovery Alliance May 2, 2018 Evotec Licenses CRISPR-Cas9 Technology From ERS Dec 4, 2017 Ncardia, Evotec Sign Licencing Agreement for iPS Cell Disease Modeling Aug 4, 2017 In Brief This Week: Thermo Fisher, Grifols, MDxHealth, Exosome Diagnostics, and More Nov 30, 2016 Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies Jul 6, 2016 Evotec Licenses CRISPR Tech From Broad Institute, Harvard Sep 11, 2014 CHDI Extends Evotec Huntington's Collaboration Through 2017 Apr 25, 2014 Evotec-Roche Deal Indicates Adoption of Mass Spec, Hi-Res Instrumentation for Clinical Protein Quant Premium Sep 12, 2013 Evotec, HSCI Ink ALS Deal Sep 6, 2013 String of Recent Deals Suggests Ag-Bio Market an Opportunity for Chemical Proteomics Firms Premium Aug 21, 2013 Evotec, Jain Foundation Expand Muscular Dystrophy Collaboration Jul 9, 2013 Evotec, Dow AgroSciences Enter Proteomics Service Deal Jan 4, 2013 Evotec Inks Deal with Apeiron to Use Chemical Proteomics in Cancer Drug Development Premium Jan 3, 2013 Evotec Buys Cell-based Reagents Firm for up to $2.9M Sep 21, 2012 In Brief This Week: Roche; Life Technologies; Trovagene, Strand; Fluidigm; Wellington Partners; Proteros, UCB; Evotec May 18, 2012 GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build Premium Apr 20, 2012 UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer Premium Jul 1, 2011 Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche Premium Load More Breaking News SARS-CoV-2 Mutational Signature Associated With Mutagenic Antiviral Drug Biocartis Restructures Balance Sheet as H1 2023 Revenues Rise 12 Percent Rare Kidney Cancer Genomic Analysis Reveals Potential Target, Suggests Treatment SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.